A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy

Inclusion Criteria: * Complement Factor I (CFI) profile biomarker-positive result * Women of child bearing potential and men should remain abstinent or use contraceptive methods Exclusion Criteria: * History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD in study eye * Previous subfoveal focal laser photocoagulation in study eye * Laser photocoagulation in the study eye * Prior treatment with external-beam radiation therapy or transpupillary thermotherapy in study eye * Previous intravitreal drug administration in study eye. A single intraoperative administration of a corticosteroid during cataract surgery at least 3 months prior to screening is permitted * Previous cell-based intraocular treatment in study eye * Intraocular surgery in study eye * Uncontrolled glaucoma and history of glaucoma-filtering surgery in study eye * History of corneal transplant in study eye * GA in either eye due to causes other than AMD * Proliferative diabetic retinopathy in either eye * Active or history of neovascular (wet) AMD in either eye * History of idiopathic or autoimmune-associated uveitis, ocular or intraocular conditions, and infectious or inflammatory ocular disease * Active uveitis and infectious conjunctivitis, keratitis, scleritis or endophthalmitis * Previous systemic treatment with complement inhibitor and with inhibitors/modulators of visual cycle * Previous expression vector mediated intraocular treatments * Uncontrolled blood pressure and atrial fibrillation * Medical conditions associated with clinically significant risk for bleeding- * Predisposition or history of increased risk for infection * Active malignancy within the previous 12 months except for appropriately treated carcinoma in situ of cervix, resolved non-melanoma skin carcinoma, and prostate cancer with a Gleason score of less than or equal to 6, and a stable prostate-specific antigen for greater than or equal to (\>/=) 12 months * History of severe allergic reaction or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of lampalizumab injection * Women of child bearing potential must have a negative serum pregnancy test within 28 days prior to initiation of study treatment * Previous participation in other studies of investigational drugs